These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36709750)
21. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Huang CY; Lien R; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):479-487. PubMed ID: 29290015 [TBL] [Abstract][Full Text] [Related]
22. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468 [TBL] [Abstract][Full Text] [Related]
23. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity. Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658 [TBL] [Abstract][Full Text] [Related]
24. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors. Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066 [TBL] [Abstract][Full Text] [Related]
25. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026 [TBL] [Abstract][Full Text] [Related]
27. Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis. Jiang S; Li X; Fu M; Huanglu D; Huang J; Huang W; Hu P Int J Clin Pharm; 2023 Dec; 45(6):1317-1325. PubMed ID: 37204617 [TBL] [Abstract][Full Text] [Related]
28. Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity. Furuncuoglu U; Vural A; Kural A; Onur IU; Yigit FU Jpn J Ophthalmol; 2022 Mar; 66(2):151-158. PubMed ID: 35091863 [TBL] [Abstract][Full Text] [Related]
29. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials. Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595 [TBL] [Abstract][Full Text] [Related]
30. Reactivation of retinopathy of prematurity after ranibizumab treatment. Wong RK; Hubschman S; Tsui I Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252 [TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Sukgen EA; Koçluk Y Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793 [TBL] [Abstract][Full Text] [Related]
32. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab. Jang JH Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744 [TBL] [Abstract][Full Text] [Related]
33. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. Xu Y; Rong A; Xu W; Niu Y; Wang Z BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Bai Y; Nie H; Wei S; Lu X; Ke X; Ouyang X; Feng S Br J Ophthalmol; 2019 Apr; 103(4):494-498. PubMed ID: 30030391 [TBL] [Abstract][Full Text] [Related]
35. Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy. Liu X; Shen W; Xia W; Lu P Cutan Ocul Toxicol; 2023 Dec; 42(4):213-218. PubMed ID: 37417939 [TBL] [Abstract][Full Text] [Related]
36. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. ; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359 [TBL] [Abstract][Full Text] [Related]
37. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment. Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229 [TBL] [Abstract][Full Text] [Related]
38. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. VanderVeen DK; Cataltepe SU Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872 [TBL] [Abstract][Full Text] [Related]
39. Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity. Chen X; Zhou L; Zhang Q; Xu Y; Zhao P; Xia H J Ophthalmol; 2019; 2019():2985161. PubMed ID: 31236289 [TBL] [Abstract][Full Text] [Related]
40. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial. Fleck BW; Reynolds JD; Zhu Q; Lepore D; Marlow N; Stahl A; Li J; Weisberger A; Fielder AR; Ophthalmol Retina; 2022 Jul; 6(7):628-637. PubMed ID: 35202890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]